These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38952507)

  • 1. Outcomes of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: A tertiary center experience.
    Tahir M; Mustafa K; Ali M; Khalid D
    Pak J Med Sci; 2024 Jul; 40(6):1196-1200. PubMed ID: 38952507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Median survival time of patients after transcatheter chemo-embolization for hepatocellular carcinoma.
    Haider Z; ul Haq T; Munir K; Usman MU; Azeemuddin M
    J Coll Physicians Surg Pak; 2006 Apr; 16(4):265-9. PubMed ID: 16624189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
    Manjunatha N; Ganduri V; Rajasekaran K; Duraiyarasan S; Adefuye M
    Cureus; 2022 Aug; 14(8):e28439. PubMed ID: 36176866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma.
    Kong JY; Li SM; Fan HY; Zhang L; Zhao HJ; Li SM
    Medicine (Baltimore); 2018 Aug; 97(33):e11872. PubMed ID: 30113483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
    Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma.
    Fukushima T; Morimoto M; Kobayashi S; Ueno M; Sano Y; Kawano K; Asama H; Nagashima S; Maeda S
    Mol Clin Oncol; 2021 Jun; 14(6):119. PubMed ID: 33903825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival.
    Ajit Y; Sudarsan H; Saumya G; Abhishek A; Navneet R; Piyush R; Anil A; Arun G
    Oman Med J; 2014 Nov; 29(6):430-6. PubMed ID: 25584161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
    Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
    Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience.
    Patidar Y; ; Mukund A; Sarin SK
    Indian J Radiol Imaging; 2021 Apr; 31(2):270-276. PubMed ID: 34556907
    [No Abstract]   [Full Text] [Related]  

  • 17. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
    Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
    Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.